Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer

Xudong He,Yun Gu,Yifan Cao,Baoying Hu,Hanji Fang,Yuchao Fei,Kunpeng Lv,Xin Liu,Jieti Wang,Chao Lin,Hao Liu,Heng Zhang,He Li,Ruochen Li,Hongyong He,Jiejie Xu
DOI: https://doi.org/10.1016/j.ejca.2021.08.006
IF: 10.002
2021-11-01
European Journal of Cancer
Abstract:AimCD73 overexpression has been reported in several malignancies and is considered to be a novel immune checkpoint. However, the role and significance of CD73 in gastric cancer (GC) still remain obscure. We aim to investigate the role of CD73 expression in predicting prognosis, shaping immune contexture and guiding therapeutic strategy in GC.MethodsThe study enrolled four independent cohorts with a total of 902 patients with GC. CD73 expression and immune contexture were examined by immunohistochemistry, single-sample gene set enrichment analysis and flow cytometry. Clinical outcomes of patient subgroups were evaluated using the Kaplan–Meier curves and Cox proportional hazard analysis. All statistical tests were two-sided.ResultsCD73 was identified as an independent adverse prognostic factor for survival in GC. CD73high tumours showed a specific microenvironment with more CD8+ T cell infiltration, but these CD8+ T cells displayed a dysfunctional phenotype. Furthermore, the CD73 (NT5E) mRNA level was associated with the Cancer Genome Atlas molecular subtypes, and NT5E high tumours showed significant fibroblast growth factor receptor 2 activation and vascular endothelial growth factor and receptor enrichment. In addition, CD73high tumours indicated better chemotherapeutic responsiveness to fluorouracil yet a worse objective response rate to pembrolizumab in GC.ConclusionsHigh CD73 expression indicated an immunoevasive contexture with CD8+ T cell dysfunction and represented an independent predictor for adverse clinical outcomes. As a potential immunotherapeutic target, CD73 could potentially be a novel biomarker for adjuvant chemotherapy, targeted therapies and immunotherapy. The crucial role of CD73 in the therapeutic landscape of GC needs further validation retrospectively and prospectively.
oncology
What problem does this paper attempt to address?